314 related articles for article (PubMed ID: 25422486)
21. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Rajkumar SV; Lacy MQ; Kyle RA
Blood Rev; 2007 Sep; 21(5):255-65. PubMed ID: 17367905
[TBL] [Abstract][Full Text] [Related]
22. New insights into therapeutic targets in myeloma.
Anderson KC
Hematology Am Soc Hematol Educ Program; 2011; 2011():184-90. PubMed ID: 22160032
[TBL] [Abstract][Full Text] [Related]
23. Smoldering multiple myeloma: biology, clinical manifestations and management.
Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
[TBL] [Abstract][Full Text] [Related]
24. [Multiple myeloma].
Abe M; Miki H; Nakamura S
Rinsho Ketsueki; 2016 Mar; 57(3):260-9. PubMed ID: 27076236
[TBL] [Abstract][Full Text] [Related]
25. Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials.
Offidani M; Leoni P; Corvatta L; Polloni C; Gentili S; Liberati AM; Pulini S; Gozzetti A; Ballanti S; Nozzoli C; Palumbo A
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):353-60. PubMed ID: 21030348
[TBL] [Abstract][Full Text] [Related]
26. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations.
Bladé J; Dimopoulos M; Rosiñol L; Rajkumar SV; Kyle RA
J Clin Oncol; 2010 Feb; 28(4):690-7. PubMed ID: 20026810
[TBL] [Abstract][Full Text] [Related]
27. State of the science in smoldering myeloma: Should we be treating in the clinic?
Hill E; Dew A; Kazandjian D
Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.
Landgren O
Hematology Am Soc Hematol Educ Program; 2013; 2013():478-87. PubMed ID: 24319222
[TBL] [Abstract][Full Text] [Related]
29. Novel targeted agents in the treatment of multiple myeloma.
Varga C; Laubach J; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Hematol Oncol Clin North Am; 2014 Oct; 28(5):903-25. PubMed ID: 25212889
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form.
Rago A; Grammatico S; Za T; Levi A; Mecarocci S; Siniscalchi A; De Rosa L; Felici S; Bongarzoni V; Piccioni AL; La Verde G; Pisani F; Franceschini L; Paviglianiti AL; Caravita T; Petrucci MT; De Stefano V; Cimino G;
Cancer; 2012 Nov; 118(22):5544-9. PubMed ID: 22786730
[TBL] [Abstract][Full Text] [Related]
31. Thalidomide as initial therapy for early-stage myeloma.
Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE
Leukemia; 2003 Apr; 17(4):775-9. PubMed ID: 12682636
[TBL] [Abstract][Full Text] [Related]
32. [The pathology of smoldering multiple myeloma].
Shibayama H
Nihon Rinsho; 2015 Jan; 73(1):33-7. PubMed ID: 25626300
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma.
Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice.
Castelli R; Cannavò A; Conforti F; Grava G; Cortelezzi A
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):740-53. PubMed ID: 22401643
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs.
Morabito F; Gentile M; Mazzone C; Bringhen S; Vigna E; Lucia E; Recchia AG; Raimondo FD; Musto P; Palumbo A
Eur J Haematol; 2010 Sep; 85(3):181-91. PubMed ID: 20491882
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
37. The Role of Early Intervention in High-Risk Smoldering Myeloma.
Joseph NS; Dhodapkar MV; Lonial S
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141
[TBL] [Abstract][Full Text] [Related]
38. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
Rajkumar SV; Buadi F
Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
[TBL] [Abstract][Full Text] [Related]
39. How I approach smoldering multiple myeloma.
Vaxman I; Gertz MA
Blood; 2022 Aug; 140(8):828-838. PubMed ID: 35576526
[TBL] [Abstract][Full Text] [Related]
40. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
